Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.MarketBeat
- Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.MarketBeat
- Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
- Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $28.00 price target on the stock.MarketBeat
- Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]Yahoo! Finance
MAZE
Sec Filings
- 2/28/25 - Form SEC
- 2/28/25 - Form SEC
- 2/10/25 - Form SCHEDULE
- MAZE's page on the SEC website